Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Aadi Bioscience Inc - SIC # 2834 - PHARMACEUTICAL PREPARATIONS
Ticker
Exchange
SIC #
Website
Latest Ticker
AADI
Nasdaq
2834
https://aadibio.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Aadi Bioscience Inc
Aadi Bioscience to Present New Non-clinical Data Highlighting Combinability of nab-Sirolimus at the American Association for Cancer Research (AACR) Annual Meeting
- Apr 9th, 2024 12:00 pm
Aadi Bioscience Presents New Subgroup Analysis of Patients with Advanced Malignant PEComa of Gynecologic Origin Treated with nab-Sirolimus at Society of Gynecologic Oncology (SGO)
- Mar 17th, 2024 12:00 pm
Aadi Bioscience Full Year 2023 Earnings: US$2.44 loss per share (vs US$2.69 loss in FY 2022)
- Mar 14th, 2024 10:36 am
Aadi Bioscience Announces Financial Results for the Fourth Quarter and Full-Year 2023 and Provides Corporate Update
- Mar 13th, 2024 12:00 pm
Aadi Bioscience to Report Fourth Quarter and Full-Year 2023 Results and Corporate Update
- Mar 6th, 2024 1:00 pm
Aadi Bioscience to Present Multiple Posters at the American Association for Cancer Research (AACR) Annual Meeting 2024
- Mar 5th, 2024 9:30 pm
Aadi Bioscience Announces Publication of Long-Term Efficacy and Safety Data Further Supporting FYARRO® for the Treatment of Malignant PEComa
- Mar 1st, 2024 9:08 pm
Aadi Bioscience to Present at the TD Cowen 44th Annual Healthcare Conference
- Feb 26th, 2024 9:05 pm
Aadi Bioscience Announces Poster Presentations at the 2024 American Society of Clinical Oncology (ASCO) Genitourinary (GU) Cancers Symposium
- Jan 26th, 2024 9:05 pm
Aadi Bioscience Announces Poster Presentations at the 2024 American Society of Clinical Oncology (ASCO) Gastrointestinal (GI) Cancers Symposium
- Jan 19th, 2024 9:05 pm
Aadi Bioscience Reports Interim Results from PRECISION1 Trial of nab-Sirolimus Demonstrating Anti-Tumor Activity in Solid Tumors with TSC1 or TSC2 Inactivating Alterations
- Dec 14th, 2023 9:05 pm
Aadi Bioscience, Inc. (NASDAQ:AADI) is definitely on the radar of institutional investors who own 39% of the company
- Dec 13th, 2023 11:12 am
Aadi Bioscience Reports Financial Results for the Third Quarter 2023 and Provides Corporate Update
- Nov 8th, 2023 1:00 pm
Aadi Bioscience to Participate in Jefferies London Healthcare Conference
- Nov 6th, 2023 9:05 pm
Aadi Bioscience to Report Third Quarter 2023 Results and Operational Update
- Nov 1st, 2023 8:05 pm
Aadi Bioscience Announces Poster Presentations on Nab-Sirolimus at the International Gynecologic Cancer Society (IGCS) 2023 Annual Global Meeting
- Oct 19th, 2023 8:05 pm
Aadi Bioscience Announces Poster Presentations at 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
- Oct 12th, 2023 8:05 pm
Aadi Bioscience Announces Poster Presentations at the North American Neuroendocrine Tumor Society (NANETS) 2023 Multidisciplinary NET Medical Symposium
- Oct 5th, 2023 8:05 pm
Aadi Bioscience Grants New CEO Dave Lennon, Ph.D. Inducement Award Under Nasdaq Listing Rule 5635 (c)(4)
- Oct 3rd, 2023 8:05 pm
Aadi Bioscience Appoints Dave Lennon, Ph.D. as President and Chief Executive Officer
- Oct 2nd, 2023 12:00 pm
Scroll